Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17012032 | 0.79 | ACACB (0.43) | BCHEACHE | |
| SCHEMBL1160564 | 0.78 | MDM4 (0.36) | ACHEMCHR1PIK3CAPRKDCMDM2 | |
| SCHEMBL12239384 | 0.77 | ACHE (0.39) | BCHEACHE | |
| SCHEMBL1160598 | 0.74 | MCHR1 (0.35) | MCHR1PRKDCCNR1CNR2IDH1 | |
| SCHEMBL1160583 | 0.72 | MAPT (0.37) | MCHR1PRKDCCNR1TP53 | |
| SCHEMBL1159680 | 0.69 | PRKDC (0.36) | MCHR1PRKDC | |
| SCHEMBL12239386 | 0.67 | ACHE (0.36) | BCHEACHECRHR1 | |
| SCHEMBL11963692 | 0.66 | DRD4 (0.32) | — | |
| SCHEMBL16256582 | 0.66 | CYP26A1 (0.36) | ACHEPIK3CACNR1CNR2TP53 | |
| SCHEMBL515998 | 0.65 | ACHE (0.33) | BCHEACHECNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459547-B1 | HERBICIDALLY ACTIVE HETEROARYL-SUBSTITUTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2459547-B1 | HERBICIDALLY ACTIVE HETEROARYL-SUBSTITUTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20120202691-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202691-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202691-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2459547-A1 | HERBICIDALLY ACTIVE HETEROARYL-SUBSTITUTED CYCLIC DIONES OR DERIVATIVES THEREOF | Syngenta Limited (GB) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012862-A1 | HERBICIDALLY ACTIVE HETEROARYL-SΥBSTITΥTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012862-A1 | HERBICIDALLY ACTIVE HETEROARYL-SΥBSTITΥTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202691-A1 | NOVEL HERBICIDES | DDT, HCN1, HDHD5 | BCHE 465/4885ACHE 177/4885MCHR1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.